MarketMoodz
QURE — uniQure N.V.
Is QURE overbought or oversold? Here is the current MarketMoodz read.
uniQure N.V. (QURE) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $47.38. The rating moved from Neutral to Overbought on July 31, 2026.
- Public ratingOverbought (as of August 19, 2026)
- Last close$47.38
- Last changeMoved from Neutral to Overbought on July 31, 2026
- SectorHealthcare
- IndustryBiotechnology
See all overbought Healthcare stocks →
AI analysis
uniQure combines a focused gene‑therapy technology base and exposure to high‑value specialty indications with the potential for value‑creating clinical and partnership catalysts. Current market tone for growth and biologics is supportive, but near‑term performance will hinge on clinical readouts, manufacturing execution and financing dynamics. The company presents asymmetric upside if programs progress and partnerships materialize, offset by elevated execution and regulatory risks that can cause significant share price swings.
Key factors
- Proprietary gene‑therapy platform with differentiated delivery/ vector expertise that supports near‑ and mid‑term clinical and licensing value
- Addressable markets in rare genetic and specialty indications that carry high per‑patient revenue potential if clinical and regulatory milestones are met
- Sector tailwinds for biologics, CRO/CDMO demand and fill/finish capacity that can improve commercial economics and partner interest
- Potential upcoming clinical/regulatory readouts or partner updates that could re‑rate shares if positive
- Market rotation into growth/biotech names and constructive intraday sentiment increases the likelihood of positive short‑term technical momentum
- Partnership/licensing optionality that could de‑risk programs via upfronts or milestone payments and reduce capital burden
Risks
- Clinical trial failure or disappointing efficacy/safety data that would materially reduce valuation for lead programs
- Manufacturing and supply‑chain execution risk for complex gene therapies, including scale‑up, lot consistency and regulatory inspection outcomes
- Payer pushback, pricing pressure and reimbursement uncertainty for high‑cost one‑time or specialty therapies
- Capital intensity and potential for dilution if cash burn continues without near‑term partnering or revenue; financing terms could be unfavorable
- Intense competition from larger, better‑capitalized gene‑therapy and biologics companies targeting similar indications
- Regulatory delays or additional data requests that extend timelines and increase development costs
- Macro/geopolitical volatility or sector rotation away from growth names that can amplify share price volatility
Latest MarketMoodz coverage
- FDA Accelerated Pathway Spurs uniQure Surge, Shifts Biotech Bets2026-06-18
- FDA Signals AMT-130 Data Could Support Accelerated Approval2026-06-17
- Moderna, Capricor Lead Biotech Movers on FDA Shakeups and HOPE-3 Data2026-03-09
- FDA Defends Placebo Trial for uniQure Huntington's Gene Therapy2026-03-05
- UniQure stock slides 40% after FDA signals AMT-130 data can't support filing2026-03-02
See today's live rating, score and targets
Members see the live hourly rating for QURE — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.